New implant aims to simplify dialysis fistula monitoring
NCT ID NCT04896476
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new device called EchoMark LP, which is implanted near a surgically created blood vessel connection (fistula) used for dialysis. The device works with a special ultrasound system (EchoSure) to measure blood flow, depth, and diameter of the fistula. The trial involved 20 adults with kidney disease who needed a fistula, and its main goal was to see if the implant is safe and if the measurements can be taken successfully.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- EchoMark LP implant and EchoSure diagnostic ultrasound system
- What this could lead to
- If successful, this device could make it easier and safer to monitor arteriovenous fistulas in dialysis patients, potentially reducing complications.
- What could go wrong
- This is a very small, early feasibility study with only 20 participants. It is designed to test safety and basic function, not to prove the device improves health outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
20 people
The number who actually took part.
- Started
-
Jan 2022
- Finished
-
Apr 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Males or non-pregnant, non-breastfeeding females ≥ 18 years of age but \< 85 years of age at the time of informed consent 2. Subject is able and willing to provide written informed consent prior to receiving any non-standard of care, protocol specific procedures 3. Subject is willing and capable of complying with all required follow-up visits 4. Subject and/or Care Team agree that the distance and transportation resources from the subject's home to the clinic are reasonable for study participation and compliance 5. Subject has an estimated life expectancy \> 18 months 6. Subject is ambulatory (cane or walker are acceptable) 7. Subjects presenting for upper arm autologous arteriovenous fistula creation 8. Vein diameter \> 2.5 mm at the antecubital fossa via imaging 9. Artery diameter \> 3 mm via imaging 10. Subject is not participating in another investigational clinical trial that has not met its primary endpoint. Participation in a post-market registry is acceptable. Exclusion Criteria: 1. Subjects receiving a forearm fistula. 2. Subject has history of Steal Syndrome. 3. Subject who is immunocompromised or immunosuppressed. 4. Subject has had three previous failed AV fistulae for hemodialysis access 5. Subjects expecting to undergo major surgery within 60 days from the EchoMark implantation. 6. Known or suspected active infection on the day of the index procedure. 7. Subjects who had infection(s) in the 30-day window prior to EchoMark placement to reduce the likelihood of partially treated infections that can seed the device and fistula 8. Subjects with diagnosed bleeding disorder, thrombocytopenia (platelet count \<50,000), hypercoagulability, and history of recurrent deep vein thrombosis not related to AV access 9. Subjects with active malignancy 10. Subjects with a history of poor compliance with the dialysis protocol 11. Subjects with a known or suspected allergy to any of the device materials 12. Subjects with an existing fistula or graft 13. Subjects who are pregnant, plan to become pregnant, or are breastfeeding.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Arteriovenous fistula are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Michgan Vascular Center
Flint, Michigan, 48507, United States
-
SKI Vascular Center
Peoria, Arizona, 85381, United States
-
Surgical Specialist of Charlotte
Charlotte, North Carolina, 28207, United States
-
Trinity Research Group
Dothan, Alabama, 36301, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a deep breath and a hint of lemongrass take the sting out of dialysis needles?
- Can better training get doctors to talk about what matters most to dying veterans?
- Can pedaling during dialysis make red blood cells more flexible?
- 30,000 dialysis patients tracked to map what works
- Donated artery grafts tested as lifeline for dialysis patients
- Does better dialysis keep parathyroid hormone in check?